Fosun Pharma Schedules 25 August 2026 Board Meeting to Approve 1H26 Results

Bulletin Express08-13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) has set 25 August 2026 for a board meeting to review and approve the consolidated interim results for the six months ended 30 June 2026 and to arrange their subsequent publication.

The notification, released on 13 August 2026 from Shanghai, notes that Chairman Chen Yuqing will preside over the session. The Board currently comprises five executive directors, two non-executive directors, four independent non-executive directors and one employee director, reflecting a diversified governance structure.

No additional financial figures or operational details were disclosed in this announcement; further information is expected upon formal release of the interim results following the meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment